- Home
- LSAK vs MNPR Comparison
LSAK vs MNPR Comparison
Compare LSAK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- MNPR
- Stock Information
- Founded
- LSAK 1997
- MNPR 2014
- Country
- LSAK South Africa
- MNPR United States
- Employees
- LSAK N/A
- MNPR N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- LSAK Finance
- MNPR Health Care
- Exchange
- LSAK Nasdaq
- MNPR Nasdaq
- Market Cap
- LSAK 384.3M
- MNPR 390.5M
- IPO Year
- LSAK N/A
- MNPR 2019
- Fundamental
- Price
- LSAK $4.29
- MNPR $100.16
- Analyst Decision
- LSAK
- MNPR Strong Buy
- Analyst Count
- LSAK 0
- MNPR 12
- Target Price
- LSAK N/A
- MNPR $89.82
- AVG Volume (30 Days)
- LSAK 70.6K
- MNPR 78.9K
- Earning Date
- LSAK 11-05-2025
- MNPR 11-07-2025
- Dividend Yield
- LSAK N/A
- MNPR N/A
- EPS Growth
- LSAK N/A
- MNPR N/A
- EPS
- LSAK N/A
- MNPR N/A
- Revenue
- LSAK $659,702,000.00
- MNPR N/A
- Revenue This Year
- LSAK N/A
- MNPR N/A
- Revenue Next Year
- LSAK N/A
- MNPR N/A
- P/E Ratio
- LSAK N/A
- MNPR N/A
- Revenue Growth
- LSAK 16.92
- MNPR N/A
- 52 Week Low
- LSAK $3.39
- MNPR $4.50
- 52 Week High
- LSAK $5.60
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- LSAK 46.75
- MNPR 88.01
- Support Level
- LSAK $4.00
- MNPR $72.41
- Resistance Level
- LSAK $4.29
- MNPR $105.00
- Average True Range (ATR)
- LSAK 0.18
- MNPR 7.18
- MACD
- LSAK 0.02
- MNPR 2.83
- Stochastic Oscillator
- LSAK 53.23
- MNPR 88.40
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.